Methocarbamol vs. Oxybutynin for Pain After Ureteroscopy
This study is comparing two medications, Methocarbamol and Oxybutynin, to see which is more effective at reducing pain and discomfort after a ureteroscopy procedure for kidney stones. A ureteroscopy is a common surgery to remove kidney stones, and a ureteral stent (a small tube) is often placed afterward, which can cause pain. You may be able to join if you are between 18 and 80 years old, have kidney stones, and are having a ureteroscopy with stent placement. The study will measure your discomfort and pain, and how you feel about the stent, one week after the procedure. The current status of this study is unclear.
- Study design
- This is an interventional study planning to enroll 126 participants. Participants will be randomly assigned to receive either Methocarbamol or Oxybutynin in addition to standard pain medication.
- What's involved
- You will receive either oral Methocarbamol 750mg every six hours as needed or oral Oxybutynin XL 10mg daily, along with other standard pain medications, after your ureteroscopy.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your discomfort, pain, and ureteral stent symptoms will be measured one week after the procedure.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Methocarbamol vs Oxybutynin for Management of Pain and Discomfort S/P Ureteroscopy Procedure
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Patient discomfort/pain after ureteroscopy and ureteral stent placement1 week
Patients will be administered the VAS pain scale to assess pain scores (score from 1-10). The VAS pain scale will be administered at the time of study enrollment, daily from POD1 until the day of stent removal, and 1 day after the stent is removed.
- Patient ureteral stent symptoms after ureteroscopy and ureteral stent placement1 week
Patients will be administered the PROMIS questionnaire, which has been validated for assessing ureteral stent symptoms. The questionnaire will be administered at the time of study enrollment, daily from POD1 until the day of stent removal, and 1 day after the stent is removed.